AU6220398A - Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity - Google Patents

Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity

Info

Publication number
AU6220398A
AU6220398A AU62203/98A AU6220398A AU6220398A AU 6220398 A AU6220398 A AU 6220398A AU 62203/98 A AU62203/98 A AU 62203/98A AU 6220398 A AU6220398 A AU 6220398A AU 6220398 A AU6220398 A AU 6220398A
Authority
AU
Australia
Prior art keywords
scarring
receptor
mediated activity
inhibiting interleukin
reducing fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62203/98A
Inventor
Mark William James Ferguson
Sharon O'kane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Victoria University of Manchester
Original Assignee
Victoria University of Manchester
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victoria University of Manchester, University of Manchester filed Critical Victoria University of Manchester
Publication of AU6220398A publication Critical patent/AU6220398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
AU62203/98A 1997-02-13 1998-02-13 Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity Abandoned AU6220398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9702944 1997-02-13
GBGB9702944.1A GB9702944D0 (en) 1997-02-13 1997-02-13 Reducing fibrosis
PCT/GB1998/000319 WO1998036061A2 (en) 1997-02-13 1998-02-13 Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity

Publications (1)

Publication Number Publication Date
AU6220398A true AU6220398A (en) 1998-09-08

Family

ID=10807559

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62203/98A Abandoned AU6220398A (en) 1997-02-13 1998-02-13 Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity

Country Status (3)

Country Link
AU (1) AU6220398A (en)
GB (1) GB9702944D0 (en)
WO (1) WO1998036061A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818278D0 (en) * 1998-08-22 1998-10-14 Smith & Nephew Compositions
EP1129190B2 (en) 1998-11-13 2017-01-11 Immunex Corporation Human tslp dna and polypeptides
EP1939293A3 (en) * 2000-06-30 2008-07-09 ZymoGenetics, Inc. Interferon-Like Protein ZCYTO21
DK1417231T3 (en) 2001-07-23 2013-07-22 Immunex Corp MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN
EP1572103A4 (en) * 2002-11-15 2008-02-13 Centocor Inc Anti-angiogenic uses of il-6 antagonists
EP1673396A1 (en) * 2003-09-22 2006-06-28 BioVation GmbH & Co.KG. Use of antibodies for reducing the biological effectiveness of il-6
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
CA2625773C (en) 2005-10-14 2015-05-12 Fukuoka University Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
BRPI0617664B8 (en) * 2005-10-21 2021-05-25 Chugai Pharmaceutical Co Ltd use of an antibody recognizing IL-6 for the production of a pharmaceutical composition to treat myocardial infarction or suppress left ventricular remodeling after myocardial infarction
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
EP1990060B1 (en) 2006-01-27 2016-09-28 Keio University Therapeutic agents for diseases associated involving choroidal neovascularization
WO2007116962A1 (en) 2006-04-07 2007-10-18 Osaka University Muscle regeneration promoter
JP2009545319A (en) 2006-08-03 2009-12-24 バクシネックス，インコーポレーテッド Anti-IL-6 monoclonal antibody and use thereof
TWI438208B (en) 2007-01-23 2014-05-21 Chugai Pharmaceutical Co Ltd Agents for suppressing chronic rejection reaction
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
CA2728243C (en) 2008-06-05 2020-03-10 National Cancer Center Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
EP4115906A1 (en) 2010-05-28 2023-01-11 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
US10155742B2 (en) 2012-01-13 2018-12-18 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
GB201522186D0 (en) * 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
WO2018109174A2 (en) 2016-12-16 2018-06-21 Singapore Health Services Pte Ltd Il-11 antibodies
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
JP7185884B2 (en) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター METHOD FOR PREDICTING AND DETERMINING THERAPEUTIC EFFECT OF IL-6 AND NEUTROPHIL-RELATED DISEASE
CA3070089A1 (en) * 2017-07-19 2019-01-24 Auckland Uniservices Limited Cytokine modulation
KR20200074160A (en) 2017-10-20 2020-06-24 가꼬우호우징 효고 이카다이가쿠 Pharmaceutical composition for inhibiting post-surgical adhesion containing anti-IL-6 receptor antibody
WO2019237125A1 (en) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase
EP3914621A1 (en) 2019-01-21 2021-12-01 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
JP3525221B2 (en) * 1993-02-17 2004-05-10 味の素株式会社 Immunosuppressants
WO1994025036A1 (en) * 1993-04-30 1994-11-10 Chugai Seiyaku Kabushiki Kaisha Expression inhibitor containing antisense oligonucleotide derivative against human interleukin-6 receptor
CZ298790B6 (en) * 1994-10-21 2008-01-30 Kishimoto@Tadamitsu Pharmaceutical composition for prevention or treatment of cachexia
IT1274782B (en) * 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio METHOD FOR SELECTING SUPERAGONISTS, ANTAGONISTS AND SUPERANTAGONISTS OF HORMONES OF WHICH RECEPTOR COMPLEX IS PART OF GP 130
AU3193097A (en) * 1996-06-20 1998-01-07 Koster, Henk W. Il-6 and il-6-receptor derived peptides having il-6 antagonistic or agonistic activity

Also Published As

Publication number Publication date
GB9702944D0 (en) 1997-04-02
WO1998036061A3 (en) 1998-11-12
WO1998036061A2 (en) 1998-08-20

Similar Documents

Publication Publication Date Title
AU6220398A (en) Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity
AU6244098A (en) Distributed game
AU3741699A (en) Personal location system
AU4943200A (en) Modified cytokine
AU3206697A (en) Ribozyme-mediated gene replacement
AU5203698A (en) Fluid-treatment assemblies
AU2321397A (en) Construction block structure
EP0903415A3 (en) Structure expansée
AU8165298A (en) Cardiotrophin-like cytokine
AU7474998A (en) Haloisoquinoline carboxamide
AU7020398A (en) Personal communications system
AU9367198A (en) Enzymatic modification
AU1365499A (en) Pre-orienting nozzle
AU6673898A (en) Factor x variant
AU3702399A (en) Catalytically active structure
AU6230398A (en) Thrombolytic agent
AU1873499A (en) Semi-submersible structure
AU8736698A (en) Shale-stabilizing additives
AU7308300A (en) Agents for reducing cholesterol-uptake and liquid-uptake
AU4715497A (en) Cytokine production inhibitors
AU7162898A (en) Regioisomeric benzothiopyranopyridines having antitumor activity
AU8808098A (en) Bis-acridinecarboxamides having antitumor activity
AU7226598A (en) Stay
AU4414699A (en) Printhead attachment structure and method
AU3194197A (en) Stainblocking agent